Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
NEW YORK, Feb. 03, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the first quarter ended December 31, 2015 after the market close on Tuesday, February 9, 2016. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.
| Conference Call & Webcast | |
| Tuesday, February 9 at 5:00pm Eastern Time | |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13629898 |
| Webcast with Slides: | http://public.viavid.com/index.php?id=118193 |
| Replays – Available through February 16, 2016 | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 13629898 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
